AI Article Synopsis

Article Abstract

Objectives: to investigate differences in amenable mortality among Italian Regions using the lists of causes of death conceived by Nolte and McKee, and Tobias and Yeh, and assess whether these differences are in part attributable to the list used. We also estimated the contribution of amenable mortality to the gaps in all-cause mortality among North, Centre and South of Italy.

Design: cross-sectional study. SETTING AND PARTICIPANTS: Italian National Institute of Statistics (ISTAT) mortality data for the period 2006-2009.

Main Outcome Measures: age- and gender-standardised amenable mortality rates.

Results: for the period 2006-2009, in Italy the Nolte and McKee mortality rate was 62.38 per 100,000 inhabitants, ranging from 54.92 in the Autonomous Province of Bolzano (Northern Italy) to 62.38 in Campania Region (Southern Italy). For the same period, the Tobias and Yeh mortality rate was 69.59 per 100,000, ranging from 60.06 in Marche Region (Central Italy) to 88.12 in Campania Region. Using Nolte and McKee's list, amenable mortality accounted for 40.65% of the differences in all-cause mortality between Northern and Southern Italy, and for 33.66% of the differences between Southern and Central Italy. Using Tobias and Yeh's list, amenable mortality accounted for 53.99% of the differences in all-cause mortality between Northern and Southern Italy, and for 42.62% of the differences between Southern and Central Italy.

Conclusion: the findings here presented show that amenable mortality rates calculated using Tobias and Yeh's list were higher than rates calculated using Nolte and McKee's list. Geographical pattern of amenable mortality derived by the two lists were almost coincident. Moreover, amenable mortality makes a substantial contribution to inequalities in health among North, Centre and South of Italy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

amenable mortality
32
mortality
14
all-cause mortality
12
southern italy
12
amenable
8
nolte mckee
8
tobias yeh
8
north centre
8
centre south
8
italy
8

Similar Publications

The Role of Pentacyclic Triterpenoids in Non-Small Cell Lung Cancer: The Mechanisms of Action and Therapeutic Potential.

Pharmaceutics

December 2024

Division of Pulmonology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan 50612, Republic of Korea.

Lung cancer remains a major global health problem because of its high cancer-related mortality rate despite advances in therapeutic approaches. Non-small cell lung cancer (NSCLC), a major subtype of lung cancer, is more amenable to surgical intervention in its early stages. However, the prognosis for advanced NSCLC remains poor, owing to limited treatment options.

View Article and Find Full Text PDF

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.

Lancet

January 2025

Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain. Electronic address:

Article Synopsis
  • TACE is the standard treatment for patients with unresectable, non-metastatic hepatocellular carcinoma, and this study evaluates the effectiveness of adding lenvatinib and pembrolizumab to TACE compared to a placebo.
  • The multicenter, randomised, double-blind phase 3 study (LEAP-012) involved participants from 137 sites across 33 countries who were randomly assigned to receive either TACE with the new drugs or TACE with a placebo.
  • The primary endpoints were progression-free survival and overall survival, and the results reported are from the first interim analysis, which serves as the final analysis for progression-free survival.
View Article and Find Full Text PDF

Current advance in comprehensive management of hilar cholangiocarcinoma and navigation in surgery: non-systematic reviews.

Int J Surg

December 2024

Hepatobiliary Surgery Department, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Article Synopsis
  • Hilar cholangiocarcinoma (h-CCA) is a challenging cancer that starts in the bile duct's epithelial cells, often diagnosed at advanced stages, leading to high mortality rates.
  • For patients who can't undergo surgery, systemic therapy and emerging immunotherapies provide new hope, while radical surgery remains the best option for improved survival.
  • Advancements in imaging technologies and techniques, such as near-infrared fiberscopes, are enhancing surgeons' ability to achieve tumor-free margin resections during operations.
View Article and Find Full Text PDF

Inborn errors of metabolism (IEMs) are rare genetic conditions with significant morbidity and mortality. Technological advances have increased therapeutic options, making it challenging to remain up to date. A centralized therapy knowledgebase is needed for early diagnosis and targeted treatment.

View Article and Find Full Text PDF

Lupus Nephritis and Chronic Kidney Disease: A Scoping Review.

Nephrology (Carlton)

January 2025

Division of Nephrology, School of Clinical Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR.

Prevention of end-stage kidney disease (ESKD) is a major objective in the management of patients with lupus nephritis (LN). Chronic kidney disease (CKD) of variable severity is common in these patients, but recent literature has mostly focused on novel immunosuppressive treatments for acute LN, while the data on CKD is relatively limited. This scoping review aims to summarise available data on the prevalence and risk factors for CKD in patients with LN.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!